Nordic Nanovector ASA - allocation of PSUs

OSLO, Norway, Sept. 20, 2021 /PRNewswire/ -- The Board of Directors of Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") has on 20 September 2021 decided to grant 350,000 Performance Share Units ("PSUs") to the Company's new CEO and primary insider Mr. Erik Skullerud in accordance with the authorisation granted at the Annual General Meeting held on 28 April 2021 (the "AGM").

The terms and conditions of the PSUs, which are part of the Company's long-term incentive plan for employees, are described on pages 25-27 in the Company's annual report for 2020.

The PSUs are granted without consideration. The PSUs are non-transferable and will vest three years after the date of grant subject to satisfaction of the applicable vesting conditions. Each vested PSU will give the holder the right to acquire one share in the Company at an exercise price corresponding to the par value of the shares being NOK 0.20.

In accordance with the resolution at the AGM, the PSUs are secured by a corresponding number of free-standing warrants. The sole purpose of the warrants is to ensure delivery of shares in the Company upon exercise of the PSUs. The warrants do not give the PSU holders (or the option holders) a right to subscribe for any additional shares in the Company.

Mr. Skullerud will hold 350,000 PSUs and 0 shares after the transaction.

The allocation of PSUs is in accordance with the Board of Director's declaration on salaries and other remuneration to the senior executive management, as approved by the Company's AGM.

Primary insider notification pursuant to the Market Abuse Regulation article 19 are attached.

For further information, please contact:

Jan H. Egberts, Chairman

Cell: +31 6 1467 2518

Email: janegberts@aol.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa---allocation-of-psus,c3417882

The following files are available for download: